Professor and Vice-Chair of Neurological Surgery, Case West Reserve University School of Medicine Peter D. Cristal Chair of Neurosurgical Oncology Director of the Brain Tumor and Neuro-Oncology Program Vi
Neurosurgery
Dr. Andrew E. Sloan, MD
|
|
Give Review
Andrew Sloan is an expert in the field of Neurosurgery. He went to Harvard Medical School. Harvard Medical School is one of the top medical schools in the US. Harvard Medical School is ranked 1/12 in Research/PrimaryCare. He has 4 awards "Regional Top Doctor", "Fellow (FAANS)", "Fellow (FACS)" and "Whos Who in Medicine and Healthcare". Doctor Andrew E. Sloan, MD is a published MD. He has 35 publications published. The most current publication "Pharmacological targeting of the histone chaperone complex FACT preferentially eliminates glioblastoma stem cells and prolongs survival in preclinical models." He accepts all Medicare patients.
Publications
- Fluorescent guided surgical resection of glioma using targeted molecular imaging agents: a literature review.
- Pharmacological targeting of the histone chaperone complex FACT preferentially eliminates glioblastoma stem cells and prolongs survival in preclinical models.
- The role of emerging therapy in the management of patients with diffuse low grade glioma.
- The role of neuropathology in the management of patients with diffuse low grade glioma : A Systematic review and evidence-based clinical practice guideline.
- The role of surgery in the management of patients with diffuse low grade glioma : A Systematic review and evidence-based clinical practice guideline.
- Atracurium Besylate and other neuromuscular blocking agents promote astroglial differentiation and deplete glioblastoma stem cells.
- Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution.
- Dendritic cell immunotherapy for solid Tumors: evaluation of the DCVax(®) platform in the treatment of glioblastoma multiforme.
- Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth.
- A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.
- Comparison of Ray Tracing and Monte Carlo Calculation Algorithms for Thoracic Spine Lesions Treated With CyberKnife-Based Stereotactic Body Radiation Therapy.
- Trends in central Nervous system tumor incidence relative to other common cancers in adults, adolescents, and children in the United States, 2000 to 2010.
- The zinc finger transcription factor ZFX Is required for maintaining the tumorigenic potential of glioblastoma stem cells.
- Cancer stem cell-specific scavenger receptor CD36 drives glioblastoma progression.
- Stereotactic radiosurgery for more than four Brain metastases.
- Establishing a process of irradiating small animal Brain using a CyberKnife and a microCT scanner.
- Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial.
- Depths and grids in Brain tumors: Implantation strategies, techniques, and complications.
- Gene markers in Brain tumors: What the epileptologist should know.
- High-Throughput Flow Cytometry Screening Reveals a Role for Junctional Adhesion Molecule A as a Cancer Stem Cell Maintenance Factor.
- The Somatic Genomic Landscape of Glioblastoma.
- Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake.
- Surgical rehearsal platform: potential uses in microsurgery.
- Network signatures of survival in glioblastoma multiforme.
- Methylation markers of malignant potential in Meningiomas.
- Results of the NeuroBlate System first-in-humans Phase I clinical trial for recurrent glioblastoma: clinical article.
- Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth.
- Risk of subsequent Cancer following a primary CNS tumor.
- ACR Appropriateness Criteria(®) Spinal Bone Metastases.
- Laminin alpha 2 enables glioblastoma stem cell growth.
- Phase II Trial of Radiosurgery to Magnetic Resonance Spectroscopy-Defined High-Risk Tumor Volumes in Patients With Glioblastoma Multiforme.
- Targeted radioimmunotherapy: the role of (131)I-chTNT-1/B mAb (Cotara(®)) for treatment of high-grade Gliomas.
- Molecular subtypes of glioblastoma are relevant to lower grade glioma.
- Genome-wide methylation analyses in glioblastoma multiforme.
Schools
Harvard Medical School
University Of California Los Angeles
UCLA Med Center
MD Anderson Cancer Center
Procedures Preformed
- Cerebrospinal Fluid (CSF) Shunt - Insertion, Repair or Removal
- Craniectomy, Craniotomy, Surgery of Skull Base, Neuroendoscopy
- Dural Repair or Other Spinal Spinal Cord Repair
- Herniated Disc Surgery
- View All
Conditions Treated
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- Brain Aneurysm
- Brain Cancer
- Brain Injury
- View All
Doctors Specialties
- Neurosurgery
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Pathway X Tiered Hosp/Ind Direct Access OH
- Anthem Blue Cross Blue Shield HMO
- Anthem Blue Cross Blue Shield PPO
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- First Health (Coventry Health Care) PPO
- Golden Rule
- Medicare Advantage PFFS
- Choice Care PPO
- Medical Mutual of Ohio POS
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Mutual of Omaha
- Tricare
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- Regional Top Doctor
- Fellow (FAANS)
- Fellow (FACS)
- Whos Who in Medicine and Healthcare
Education
-
UCLA Medical Center -
Harvard Medical School
Hospital
-
University Hospitals Case Medical Center
Drug Facts
| NPI NUMBER | 1952317554 | |
| NPPES Provider LastName | SLOAN | |
| NPPES Provider FirstName | ANDREW | |
| NPPES Provider ZIPCode | 44106 | |
| NPPES Provider State | OH | |
| Specialty Description | Neurosurgery | |
| Total Claim Count | 33.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1952317554 |
| Last Name Of The Provider | SLOAN |
| First Name Of The Provider | ANDREW |
| View All |
Similar Doctors
|
Dr. Mark Luciano, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Matthew J. Likavec, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Atef A. Eltomey, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Robert T. Geertman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ghaith Habboub, MD |
|
|
Dr. Andres L. Maldonado, MD |
|
|
Dr. Sunil V. Manjila, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tatiana V. Oliveira, MD |
|
|
Dr. Adrienne M. Moraff, MD |
|
|
Dr. James M. Wright III, MD |